Work

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

Year: 2020

Type: review

Abstract: Single-agent osimertinib is the standard of care for the first-line treatment of advanced EGFR + NSCLC and remained the only marketed third-generation EGFR tyrosine kinase inhibitor (TKI) until March 2020 when almonertinib (HS-10296) was approved in the People's Republic of China for the treatment of advanced EGFR T790M+ NSCLC based on a phase 2 expansion study of a phase 1/2 trial. In this review, we profiled many of the third-generation EGFR TKIs in late-stage clinical development (e.g., almonertinib, lazertinib, alflutinib 1 1The name of ‘Alflutinib' was changed as per the requirements of the National Pharmacopoeia Committee of China and the "China drug generic naming principle", and the name of the drug has been changed from ‘Alflutinib' to ‘Furmonertinib'., rezivertinib, ASK120069, SH-1028, D-0316, and abivertinib) based on their interim results from phase 1 and phase 2 trials, and included the designs of the phase 3 trials and their chemical structures when publicly available. We also listed other third-generation EGFR TKIs in pipeline development based on the search of clinical trial registration websites. In addition, we summarized the results of clinical trials that previously reported third-generation EGFR TKIs (rociletinib, olmutinib, nazartinib, mavelertinib), including phase 3 results of rociletinib and naquotinib. We further profiled combination clinical trial design of the third-generation EGFR TKIs including FLAURA2 (NCT04035486), MARIPOSA (NCT04487080), ACROSS1 (NCT04500704), and ACROSS2 (NCT04500717) that if positive can potentially usher in the next standard of care for advanced EGFR+ NSCLC.

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2020.11.028

Authors: Misako Nagasaka, Viola W. Zhu, Sun Min Lim, Michael Greco, Fengying Wu, Sai-Hong Ignatius Ou